Segment Reporting – Corporate and Other/Merck Group

 

 

 

 

XLS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate and Other

EUR million

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

*

Figures for 2009 have been adjusted for the disclosure of commission income as well as royalty and commission expenses

**

Actual year as at June 30, 2010 – previous year as at December 31, 2009

Sales

 

 

 

 

Royalty and commission income*

 

 

 

 

Total revenues

 

 

 

 

Gross margin

 

 

 

 

Marketing and selling expenses*

 

 

 

 

–0.3

0.1

–1.4

–0.4

Royalty and commission expenses*

 

 

 

 

Administration expenses

 

 

 

 

–17.9

–14.5

–34.2

–28.4

Other operating expenses and income

 

 

 

 

18.6

–6.3

–15.5

–14.1

Research and development

 

 

 

 

–0.1

0.3

–0.1

Operating result

 

 

 

 

2.0

–20.3

–49.5

–42.9

Exceptional items

 

 

 

 

–1.2

–1.2

Earnings before interest and tax (EBIT)

 

 

 

 

0.8

–20.3

–50.7

–42.9

Net operating assets**

 

 

 

 

43.1

37.4

Segment liabilities**

 

 

 

 

–13.8

–15.7

Capital spending on property, plant and equipment

 

0.1

–0.1

0.3

–0.1

Investments in intangible assets

 

 

 

 

2.4

2.9

3.3

5.4

Depreciation

 

 

 

 

–0.5

–0.4

–1.1

–1.4

Impairment losses

 

 

 

 

Net cash flows from operating activities

 

 

 

 

–70.1

–183.2

–181.9

–265.1

Net cash flows from investing activities

 

 

 

 

–8.8

–789.7

1,336.0

–1,040.4

Free cash flow

 

 

 

 

–76.2

–185.9

–196.7

–270.6

Underlying free cash flow

 

 

 

 

–72.7

–185.9

–181.3

–270.6

FCR in %

 

 

 

 

ROS in %

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Merck Group

EUR million

 

 

 

 

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Sales

 

 

 

 

2,102.8

1,826.4

4,125.6

3,583.3

Royalty and commission income*

 

 

 

 

105.2

83.4

181.3

184.9

Total revenues

 

 

 

 

2,208.0

1,909.7

4,306.9

3,768.2

Gross margin

 

 

 

 

1,690.8

1,392.0

3,303.0

2,793.7

Marketing and selling expenses*

 

 

 

 

–540.2

–466.7

–1,008.4

–920.6

Royalty and commission expenses*

 

 

 

 

–117.3

–101.2

–239.5

–198.6

Administration expenses

 

 

 

 

–115.2

–108.1

–219.6

–214.9

Other operating expenses and income

 

 

 

 

–109.4

–44.7

–244.4

–129.8

Research and development

 

 

 

 

–338.8

–340.6

–686.0

–653.5

Operating result

 

 

 

 

326.2

184.5

621.0

382.6

Exceptional items

 

 

 

 

–1.2

–1.2

–68.8

Earnings before interest and tax (EBIT)

 

 

 

 

325.0

184.5

619.8

313.8

Net operating assets**

 

 

 

 

13,464.4

12,346.7

Segment liabilities**

 

 

 

 

–1,550.1

–1,401.0

Capital spending on property, plant and equipment

91.2

100.6

155.9

189.7

Investments in intangible assets

 

 

 

 

17.0

18.3

31.0

45.3

Depreciation

 

 

 

 

–227.4

–219.8

–447.6

–443.8

Impairment losses

 

 

 

 

–7.4

–0.2

–33.6

–0.2

Net cash flows from operating activities

 

 

 

 

466.2

192.3

744.9

475.0

Net cash flows from investing activities

 

 

 

 

–112.5

–900.2

1,157.0

–1,266.6

Free cash flow

 

 

 

 

356.4

79.2

551.2

243.2

Underlying free cash flow

 

 

 

 

359.9

79.2

566.5

243.2

FCR in %

 

 

 

 

16.3

4.1

13.2

6.5

ROS in %

 

 

 

 

14.8

9.7

14.4

10.2